8
Jan
2016

All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill